Main Article Content

Abstract

Dengue hemorrhagic fever is one infectious diseases that have high case fatality rate in Indonesia. The aim of this study was to descibe the antibody anti-dengue profile in dengue hemorrhagic fever patients at Dr. Soetomo Hospital Surabaya. This study was epidemiological descriptive study to aims prevalence primary and secondary infection of dengue hemorrhagic fever and its clinical appearances. This study used 85 samples by taking medical record data of IgM and IgG anti-dengue serologic test from Internal Medicine Department, Dr. Soetomo Hospital, Surabaya, between January to December 2010. The data were collected and analyzed in diagrams and tables. Result of this study showed 25 (29,4%) patients had positive IgM serologic test, 14 (16,4%) patients had positive IgG serologic test and 46 (54,2%) patients had positive IgM and IgG serologic test. In primary infections, the history of fever was 3.8±1.2 days; platelet counts 58,6±21,4/ml and bleeding sign 37% of 25 patients. In secondary infections, the history of fever was 4.28±1.15 days; platelet count was 44,17±24,2/ml and bleeding sign 52% of 60 patients. In conclusion, patients with secondary infection have higher prevalence than primary infection. Then in secondary infection had more severe clinical appearance than primary infection.

Keywords

dengue hemorrhagic fever antibody anti-dengue

Article Details

How to Cite
Waskito, L. A., Notopuro, P. B., & Endraswari, P. D. (2016). ANTIBODY ANTI-DENGUE PROFILE IN DENGUE HEMORRHAGIC FEVER PATIENTS AT DR. SOETOMO HOSPITAL, SURABAYA. Folia Medica Indonesiana, 51(3), 173–176. https://doi.org/10.20473/fmi.v51i3.2830

References

  1. Aryati, Soetjipto, Hariadhi S, Rantam FA, Soegijanto S. 2006. Profile serotype virus dengue di Indonesia tahun 2003–2005. Maj. Ked. Trop. Ind. (MKTI). 17(1): 72–80.
  2. Darmowandowo, Widodo (2006). Continuing Education Ilmu Kesehatan Anak ke-36, Kapita Selekta Ilmu Kesehatan Anak VI. Surabaya: SMF Ilmu Kesehatan Anak FK Unair–Dr. Soetomo Hospital Surabaya
  3. PAHO (2008). Number of reported cases of dengue and dengue hemorrhagic fever (DHF), Region of the Americas (by country and subregion). Washington, DC, Pan American Health Organization. Available from:h ttp://www.paho.org/english/ad/dpc/cd/dengue.htm
  4. Porrozzi R, Teva A, Amaral VF, Santos Da Costa MV, Grimaldi Jr G (2004). Cross-immunity experiments between different species or strains of Leishmania in rhesus macaques (Macaca mulatta). The American journal of tropical medicine and hygiene, 71 (3): 297–305
  5. Soegianto, S (2006). Patogenesa dan Perubahan Patofisiologi Infeksi Virus Dengue. Available from: http://www.pediatrik.com/buletin/20060220-8ma2gi-buletin.pdf. Accessed Mei 12, 2011.
  6. Vaughn, David (1997). Dengue in the Early Febrile Phase: Viremia and Antibody Responses. The Journal of Infectious Diseases, 176:322–30
  7. WHO (2009). Dengue Guidelines for Diagnostic, Treatment, Prevention and Control. WHO press, Jeneva
  8. Yamanaka, Atsushi, et al. (2011). Displacement of the Predominant Dengue Virus from Type 2 to Type 1 with a Subsequent Genotype Shift from IV to I in Surabaya, Indonesia 2008–2010. PLoS ONE 6(11): e27322. doi:10.1371/journal.pone.0027322